

IN THE CLAIMS

1. (currently amended) A combination useful for simultaneous, sequential or separate administration in anticancer or antiviral therapy, comprising calcium, injectable magnesium and ~~an active ingredient which releases oxalate during its metabolism~~ oxaliplatin, wherein part of the calcium is in injectable form and the other part is in oral form.

2. (cancelled)

3. (cancelled)

4. (currently amended) The combination of claim 1, wherein the calcium is present as a gluconate, ~~chloride~~, bromogalactogluconate, gluconolactate or carbonate salt, and the magnesium is present as a sulfate or pidolate salt.

5. (currently amended) The combination of claim 4, wherein part of the calcium is in injectable form and the other part is in oral form, and wherein the cation of said injectable calcium salt is present in a concentration between 8 and 20 mg/ml, and wherein the cation of said injectable magnesium salt is present in a concentration between 10 and 20 mg/ml, the concentrations being expressed as calcium or magnesium ions, respectively.

6. (currently amended) A method of ~~preventing-inhibiting~~ or treating neurotoxicity caused by the administration of a product that releases oxalate during its metabolism, comprising administering to a patient that has received, is receiving, or will receive a ~~product that releases oxalate during its metabolism~~ oxaliplatin a combination of calcium and magnesium effective to prevent or treat the neurotoxicity, wherein part of the calcium is administered to the patient in injectable form and the other part is administered in oral form.

7. (cancelled)

8. (cancelled)

9. (currently amended) The method of claim 6, wherein the calcium and magnesium are administered to the patient prior to, after, or both prior to and after administration of ~~the product that releases oxalate during its metabolism~~oxaliplatin.

10. (currently amended) The method of claim 6, wherein the calcium and magnesium are administered to the patient simultaneously with administration of ~~the product that releases oxalate during its metabolism~~oxaliplatin.

11. (previously presented) The method of claim 6, wherein said calcium and magnesium are administered separately.

12. (previously presented) The combination of claim 5, wherein the concentration of said injectable magnesium is 15 mg/ml.

13. (new) The method of claim 6, wherein said calcium in oral form is administered at a dose of 1 g/day by the oral route for the 8 days following the treatment with oxaliplatin.